Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 336,680
  • Shares Outstanding, K 70,880
  • Annual Sales, $ 19,390 K
  • Annual Income, $ -71,660 K
  • 36-Month Beta 3.11
  • Price/Sales 15.72
  • Price/Cash Flow 0.00
  • Price/Book 2.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.01 +24.69%
on 03/27/17
5.35 -6.54%
on 04/03/17
+0.90 (+21.95%)
since 03/24/17
3-Month
3.35 +49.25%
on 01/31/17
5.35 -6.54%
on 04/03/17
+1.50 (+42.86%)
since 01/26/17
52-Week
2.65 +88.68%
on 12/08/16
7.60 -34.21%
on 06/07/16
-1.63 (-24.59%)
since 04/26/16

Most Recent Stories

More News
Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from the Company's therapeutic and research programs will be presented at the 20th Annual Meeting...

SGMO : 5.00 (+5.26%)
Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Dr. Sandy Macrae, Sangamo's chief executive officer, will provide a corporate overview at the Alliance...

SGMO : 5.00 (+5.26%)
Sangamo Biosciences Up 36.4% Since SmarTrend Uptrend Call (SGMO)

SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on January 9th, 2017 at $3.74. In approximately 3 months, Sangamo Biosciences has returned 36.36% as of today's recent price of $5.10....

SGMO : 5.00 (+5.26%)
Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today the presentation of new human in vitro and animal model data demonstrating significant reduction of...

SGMO : 5.00 (+5.26%)
Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus

In today's pre-market research, Stock-Callers.com takes a closer look at four equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG), Synthetic...

SGMO : 5.00 (+5.26%)
EYEG : 2.02 (-2.42%)
SYN : 0.53 (+6.00%)
RGLS : 1.55 (+6.90%)
Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will present at the Cowen...

SGMO : 5.00 (+5.26%)
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-913, a genome...

SGMO : 5.00 (+5.26%)
Sangamo Therapeutics Announces Chief Financial Officer Succession

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced the appointment of Kathy Yi as senior vice president and chief financial officer, to succeed current...

SGMO : 5.00 (+5.26%)
NVS : 76.35 (+0.14%)
Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for...

SGMO : 5.00 (+5.26%)
Research Reports Initiation on Biotech Stocks -- Portola Pharma, Tesaro, Sangamo Therapeutics, and Cerus

This morning, Stock-Callers.com puts focus on select equities to see how they have fared over the last few trading sessions: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Tesaro Inc. (NASDAQ: TSRO), Sangamo...

SGMO : 5.00 (+5.26%)
TSRO : 142.01 (+2.58%)
PTLA : 38.77 (-2.17%)
CERS : 4.61 (+7.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sangamo BioSciences, Inc. is a leader in the development of noveltranscription factors for the regulation of gene expression. Transcriptionfactors are proteins that turn genes on or off by recognizing specific DNAsequences. The Universal Gene Recognition technology platform enables theengineering of...

See More

Support & Resistance

2nd Resistance Point 5.29
1st Resistance Point 5.14
Last Price 5.00
1st Support Level 4.75
2nd Support Level 4.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.